These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36930754)
1. Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer. Li Y; Cen Y; Tu M; Xiang Z; Tang S; Lu W; Zhang H; Xu J Research (Wash D C); 2023; 6():0070. PubMed ID: 36930754 [TBL] [Abstract][Full Text] [Related]
2. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. Tang S; Shen Y; Wei X; Shen Z; Lu W; Xu J Cell Death Dis; 2022 Sep; 13(9):826. PubMed ID: 36163324 [TBL] [Abstract][Full Text] [Related]
3. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. Bahar E; Kim JY; Kim DC; Kim HS; Yoon H Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140 [TBL] [Abstract][Full Text] [Related]
4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness. Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723 [TBL] [Abstract][Full Text] [Related]
5. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition. Li Y; Cen Y; Fang Y; Tang S; Li S; Ren Y; Zhang H; Lu W; Xu J ACS Nano; 2022 Aug; 16(8):12786-12800. PubMed ID: 35920396 [TBL] [Abstract][Full Text] [Related]
6. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496 [TBL] [Abstract][Full Text] [Related]
7. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965 [No Abstract] [Full Text] [Related]
8. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520 [TBL] [Abstract][Full Text] [Related]
9. Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance. Berckmans Y; Ene HM; Ben-Meir K; Martinez-Conde A; Wouters R; Van den Ende B; Van Mechelen S; Monin R; Frechtel-Gerzi R; Gabay H; Dor-On E; Haber A; Weinberg U; Vergote I; Giladi M; Coosemans A; Palti Y Front Oncol; 2024; 14():1402851. PubMed ID: 38993641 [TBL] [Abstract][Full Text] [Related]
10. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963 [TBL] [Abstract][Full Text] [Related]
11. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662 [TBL] [Abstract][Full Text] [Related]
12. Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant Burgess BT; Anderson AM; McCorkle JR; Wu J; Ueland FR; Kolesar JM Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32098452 [TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964 [TBL] [Abstract][Full Text] [Related]
14. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856 [TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. Gong H; Nie D; Huang Y; Li Z Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083 [TBL] [Abstract][Full Text] [Related]
17. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417 [TBL] [Abstract][Full Text] [Related]